Longevity is the cross-category bucket where peptide therapies meet wellness, telehealth, and the post-Category-2 access shift. The 2026 storyline: GLP-1 receipts have created the consumer infrastructure for peptide-based longevity, and the pharmacy-compounding pathway is reopening for compounds like BPC-157, TB-500, GHK-Cu, thymosin alpha-1, and CJC-1295/ipamorelin under physician prescription.
The defining commercial move is Hims & Hers' planned 2026 longevity specialty, covering peptides, coenzymes, and GLP/GIP treatments — built on the California peptide-manufacturing facility the company acquired in February 2025. The clinical adjunct: a March 31 Boston University paper covered on this site argued the thymus plays a larger role in immune aging than previously understood, with implications for thymic peptides like thymosin alpha-1 and thymosin beta-4. Stories here also cover the testosterone, NAD+, and copper-peptide threads that telehealth platforms increasingly bundle with the longevity label.
See #bpc-157, #tb-500, #ghk-cu, and #hims-hers for adjacent threads.
At the Aging Research and Drug Discovery (ARDD) meeting at Harvard on October 1-3, 2026, Novo Nordisk researchers reported that in protein data from 10,052 participants in five semaglutide trials, the drug lowered an estimate of heart biological age by about 2 to 4 years at the first follow-up measurement, according to the meeting's poster abstracts. Longevity.Technology reported on October 4 that Novo also modeled SELECT trial results in a UK cohort of 19,117 people to project 1.9 life-years gained, and that a Lilly epigenetic substudy with 71 paired SURMOUNT-5 participants found all 15 epigenetic clocks showed less aging than the 1.38 years that had passed, two of them statistically significant. Lilly called its work preliminary and hypothesis-generating, with no placebo or control group, and biological-age clocks are not established clinical outcomes.
The Pep Club, a direct-to-consumer telehealth platform co-founded by entrepreneur Greg Yuna (CEO) and Gabriella Shak, publicly launched Tuesday June 30, 2026 at thepepclub.com with a full-stack model pairing prescription medication therapy and physician-guided peptide protocols with at-home biomarker testing. The platform spans more than a dozen categories including weight management (GLP-1 prescriptions), hormone optimization (testosterone, thyroid), sexual health (PT-141, sildenafil, tadalafil), hair restoration (finasteride, GHK-Cu, oral minoxidil), skin and acne (tretinoin, hyaluronic acid, cosmetic peptides), IV and vitamin support, peptides (BPC-157, TB-500, ipamorelin, sermorelin among the compounded offerings), and longevity. All protocols are reviewed and supervised by licensed clinicians and fulfilled through licensed pharmacy partners. The differentiator is the at-home capillary biomarker collection device that lets patients submit lab-quality panels for personalization and monitoring. Yuna, co-founder and CEO: 'When you combine real at-home testing with both prescription and peptide therapy under licensed clinical supervision, you can actually personalize treatment to the individual.' The platform launches into a competitive telehealth market that already includes Hims & Hers, LifeMD, Henry Meds, and Ro; the Pep Club differentiator is the peptide-plus-biomarker integration.
Researchers at UC San Diego and partner institutions reported in Nature Communications on May 19, 2026 a post hoc, exploratory analysis of epigenetic aging in a 32-week, double-blind, placebo-controlled Phase 2b trial of semaglutide in adults with HIV-associated lipohypertrophy. The trial randomized 108 people; 84 with blood samples at baseline and week 32 were analyzed (semaglutide n=45, placebo n=39), and epigenetic aging was not a prespecified endpoint. Compared with placebo, semaglutide lowered annualized clock estimates for PhenoAge by 4.9 years per year (p=0.004), PCGrimAge by 3.1 (p=0.007), GrimAge V2 by 2.3 (p=0.009), and GrimAge V1 by 1.4 (p=0.042), and slowed DunedinPACE by about 9% (-0.09 units, p=0.01). The authors said the post hoc design, modest sample, HIV-specific population, and 32-week follow-up limit how widely the results apply.
A 2026 Frontiers in Aging review consolidates the case for therapeutic peptides as gerontology agents, mapping mechanisms across mitochondrial-derived peptides (MOTS-c, humanin), thymic peptides (thymosin alpha-1), wound-and-tissue-repair peptides (BPC-157, TB-500), copper peptides (GHK-Cu), and growth-hormone secretagogues (CJC-1295, ipamorelin). The review frames the longevity peptide field as a clinical category that now sits alongside GLP-1 metabolic medicine — driven by Hims & Hers' 2026 longevity-specialty launch, Drexel's May 5 Q&A on peptide popularity, and the FDA Category 2 removal of 12 peptides on April 22. The piece also flags that BPC-157, TB-500, and most wellness peptides still lack published human RCTs, with clinical use largely based on case reports and preclinical mechanistic rationale.
Hims & Hers reports Q1 2026 results May 11 after market close. Company guidance: $600–625M revenue (2–7% YoY) and $35–55M adjusted EBITDA (~7% margin), with Q1 carrying a roughly $65M timing impact from the weight-loss shift to 503A fulfillment. Outlook (ex-Eucalyptus) is $2.7–2.9B revenue and $300–375M EBITDA. Hims also launched Testosterone Rx+ — a once-daily pill for low-libido idiopathic hypogonadism — as a non-GLP-1 specialty addition, signaling the wider longevity and peptide play the company has telegraphed for 2026. The California peptide-manufacturing facility acquired in February 2025 sits as a post-PCAC option for producing reclassified Category 1 peptides if the July meeting clears the path.
Hims & Hers shares climbed roughly 9% in early-week trading from $28.82 to $31 ahead of the company's May 11 Q1 2026 earnings, extending a five-session run that has lifted the stock about 49%. The catalysts: renewed FDA interest in peptides via the upcoming July PCAC meeting and the company's Novo Nordisk collaboration providing branded Wegovy and Ozempic access. Hims also flagged a 2026 longevity specialty launch covering peptides, coenzymes, and GLP/GIP treatments, and continues to invest in the California peptide-manufacturing facility acquired in February 2025 — which could pivot to producing reclassified Category 1 peptides if the July PCAC clears the path.
The thymus — source of thymosin peptides including Thymosin Alpha-1 — has become an emerging target for healthspan, longevity, and precision oncology research.